Nav: Home

Study will determine which type 2 diabetes patients benefit most from bariatric surgery

March 10, 2017

BOSTON - (March 10, 2017) - Bariatric surgery can reverse type 2 diabetes in severely obese people, reducing or eliminating the need for medications, and improve other serious health problems such as high blood pressure and sleep apnea, but it still remains to be determined which patients with type 2 diabetes will benefit most from surgery.

Do individuals who are moderately obese also benefit from surgery? And what is the duration of improvement in diabetes after surgery? Is it lifelong? Does having surgery change the risk of complications from diabetes?

Those are precisely the kinds of questions that a new study known as ARMMS-T2D (Alliance of Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes) will tackle over the next five years, thanks to an award from the National Institutes of Health (NIH).

The research is being conducted at institutions in the ARMMS-T2D consortium, composed of Cleveland Clinic, Joslin Diabetes Center, University of Pittsburgh and the University of Washington. The coordinating center is Cleveland Clinic.

The ARMMS-T2D study is a follow-up effort from four smaller-scale, randomized controlled trials conducted at these institutions, including SLIMM-T2D (Surgery or Lifestyle with Intensive Medical Management in the Treatment of Type 2 Diabetes) conducted by Joslin and Brigham and Women's Hospital.

The SLIMM-T2D study examined whether gastric surgery (both band and bypass) or an intensive program of medical and lifestyle management (Why WAIT?) is more effective for the treatment of type 2 diabetes in overweight or mildly obese patients with type 2 diabetes. Data from this study have demonstrated that surgery is more effective in controlling diabetes than medical and lifestyle management, but longer-term information is needed.

Now, investigators from the four centers have merged data and outcomes measures from their individual clinical trials into a unified, prospective observational study that will continue to follow this unique cohort of patients, individuals previously randomized to bariatric surgical procedures or medical and lifestyle intervention.

The unique design of ARMMS T2D will provide the largest body of long-term evidence to guide practicing doctors in clinical decision making regarding the durability, efficacy, and safety profile of both treatment groups. The long-term complications and benefits are unknown because this has never been studied over a long period of time in a randomized study.

Mary-Elizabeth Patti, M.D., F.A.C.P., Director of the Hypoglycemia Clinic at Joslin Diabetes Center, is the Principal Investigator at Joslin. Over the next five years, her study team will follow up with participants at different points to take blood samples and look for new patterns in hormone secretion and improved metabolism.

"The four centers came together so we could pool the studies to get more information about how surgery changes metabolism in the long-term," says Dr. Patti. "We know that's the case in the short run, and that it's better than medical management alone, but we want to understand how surgery controls diabetes and if it does so for the long-term."

The study will include approximately 242 patients with type 2 diabetes. More than one third of these individuals have a BMI less than 35.

The study will identify the factors that result in a higher rate of long-term diabetes remission, better blood sugar control and rate of diabetes relapse after initial remission.

There is an unmet need for patients to achieve good glucose control safely, says Dr. Patti. "This study will better define who is likely to respond to gastric surgery and help answer the question, when during the course of type 2 diabetes does surgery have the greatest benefit? There's evidence that the earlier, the more effective it is. So if you wait until someone has had diabetes for 30 years it might not be as helpful."

The study will start in July.
About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

For more information, visit or follow @joslindiabetes

Joslin Diabetes Center

Related Diabetes Articles:

The role of vitamin A in diabetes
There has been no known link between diabetes and vitamin A -- until now.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
Type 2 diabetes and obesity -- what do we really know?
Social and economic factors have led to a dramatic rise in type 2 diabetes and obesity around the world.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
The Lancet Diabetes & Endocrinology: Older Americans with diabetes living longer without disability, US study shows
Older Americans with diabetes born in the 1940s are living longer and with less disability performing day to day tasks than those born 10 years earlier, according to new research published in The Lancet Diabetes & Endocrinology journal.
Reverse your diabetes -- and you can stay diabetes-free long-term
A new study from Newcastle University, UK, has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.
New cause of diabetes
Although insulin-producing cells are found in the endocrine tissue of the pancreas, a new mouse study suggests that abnormalities in the exocrine tissue could cause cell non-autonomous effects that promotes diabetes-like symptoms.
The Lancet Diabetes & Endocrinology: Reducing sugar content in sugar-sweetened drinks by 40 percent over 5 years could prevent 1.5 million cases of overweight and obesity in the UK and 300,000 cases of diabetes
A new study published in The Lancet Diabetes & Endocrinology journal suggests that reducing sugar content in sugar sweetened drinks (including fruit juices) in the UK by 40 percent over five years, without replacing them with any artificial sweeteners, could prevent 500,000 cases of overweight and 1 million cases of obesity, in turn preventing around 300,000 cases of type 2 diabetes, over two decades.
Breastfeeding lowers risk of type 2 diabetes following gestational diabetes
Women with gestational diabetes who consistently and continuously breastfeed from the time of giving birth are half as likely to develop type 2 diabetes within two years after delivery, according to a study from Kaiser Permanente published today in Annals of Internal Medicine.

Related Diabetes Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...